HIV Vaccine Work Awaits Next STEP In Merck Analysis; Failure Aids Biomarker

Plans for PAVE 100, the National Institute on Allergy and Infectious Diseases' Phase IIb HIV vaccine study, remain on hold until the next wave of Merck's STEP data - also expected to aid preclinical vaccine development - is released, researchers say